Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Halozyme Therapeutics's market cap was $11.60B on Nov 11, 2026, against $8.39B a year earlier. Over the last 5 years it ranged from $4.27B to $14.93B, with a median of $6.66B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $11.60B | +46.6% |
| 2025 | Dec 31, 2025 | $7.91B | +30.1% |
| 2024 | Dec 31, 2024 | $6.08B | +24.6% |
| 2023 | Dec 29, 2023 | $4.88B | -36.5% |
| 2022 | Dec 30, 2022 | $7.69B | +35.7% |
| 2021 | Dec 31, 2021 | $5.67B | -2.0% |
| 2020 | Dec 31, 2020 | $5.78B | +122.7% |
| 2019 | Dec 31, 2019 | $2.60B | +22.8% |
| 2018 | Dec 31, 2018 | $2.11B | -26.7% |
| 2017 | Dec 29, 2017 | $2.88B | +125.4% |
| 2016 | Dec 30, 2016 | $1.28B | -42.2% |
| 2015 | Dec 31, 2015 | $2.21B | +82.8% |
| 2014 | Dec 31, 2014 | $1.21B | -29.1% |
| 2013 | Dec 31, 2013 | $1.71B | +126.0% |
| 2012 | Dec 31, 2012 | $756.17M | -23.3% |
| 2011 | Dec 30, 2011 | $985.69M | – |
See a number that looks wrong?